Farmacosmo S.P.A.

COSMO.MI's capital structure is marked by a debt-to-equity ratio of 0.69, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is weak, with only 26,080 EUR in cash and equivalents and a negative free cash flow of -1,670,180 EUR. The current ratio of 1.44 suggests the company can cover its short-term liabilities, but the negative operating cash flow of -2,133,360 EUR raises concerns about its ability to sustain operations without external financing.

Profitability metrics are deeply negative, with a return on equity of -28.08% and a return on assets of -9.63%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The operating loss of -2,279,520 EUR and net loss of -2,972,060 EUR further underscore the company's financial distress. Gross profit of 4,162,550 EUR is insufficient to cover operating expenses, highlighting a significant operational challenge.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases exposure to regional economic downturns and shifts in consumer demand. The absence of segment-specific revenue data limits the ability to assess the performance of individual product lines or geographic regions.

Growth trajectory is negative, with the company reporting a net loss and declining profitability. Analysts estimate a mean EBIT of 2,800,000 EUR for the current fiscal year, which is a significant improvement from the reported operating loss of -2,279,520 EUR. However, the gap between actual performance and analyst expectations suggests a high degree of uncertainty. The company's capital expenditure of -1,230,890 EUR indicates ongoing investment, but the negative free cash flow suggests these investments are not yet generating positive returns.

Risk factors include liquidity constraints and the potential for dilution, although the risk of dilution is currently assessed as low. The company's negative net cash position after subtracting total debt is a key flag, indicating a need for additional financing. The risk assessment highlights the company's inability to generate positive cash flows from operations, which could lead to further financial stress.

Recent events include the publication of the latest financial results, which show a significant decline in profitability. The company's management has not disclosed specific strategic initiatives to address the operating losses, and there are no recent transcripts or filings indicating a clear path to profitability. The discrepancy between actual EPS of -0.08 EUR and the mean estimate of 0.21 EUR suggests that the market may be overly optimistic about the company's near-term performance.